OnKure Therapeutics, Inc. OKUR Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by OnKure Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about OnKure Therapeutics, Inc.'s short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OnKure Therapeutics, Inc.'s short- and long-term operating lease liabilities?
- OnKure Therapeutics, Inc. (OKUR) reported short- and long-term operating lease liabilities of -$140K in Q1 2026.
- How has OnKure Therapeutics, Inc.'s short- and long-term operating lease liabilities changed year-over-year?
- OnKure Therapeutics, Inc.'s short- and long-term operating lease liabilities decreased by 7.7% year-over-year, from -$130K to -$140K.
- What is the long-term trend for OnKure Therapeutics, Inc.'s short- and long-term operating lease liabilities?
- Over 2 years (2022 to 2025), OnKure Therapeutics, Inc.'s short- and long-term operating lease liabilities has grown at a 10.7% compound annual growth rate (CAGR), from -$437K to -$536K.